Compound 4 increased the cilia length to 6.1 ± 0.6 μm comparedwith 4.3 ± 0.3 μm of the solvent control group (Figure 3B,C), suggestingpotential therapeutic usefulness of KCa2.3 channel positivemodulators (e.g., compound 4) in ciliopathy disease stateswith abnormal cilia. This evidence concerns the gene KCNN3 and ciliopathy.